Yarrow Bioscience Inc (YARW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Yarrow Bioscience Inc (YARW) has a cash flow conversion efficiency ratio of -0.166x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.08 Million) by net assets ($24.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Yarrow Bioscience Inc for the company's overall valuation and market capitalisation.
Yarrow Bioscience Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Yarrow Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Yarrow Bioscience Inc (YARW) stock price for real-time trading data and today's change.
Yarrow Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yarrow Bioscience Inc ranked by their cash flow conversion efficiency. Review YARW FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zimmite Taiwan Ltd
TWO:8435
|
0.059x |
|
Huvitz Co. Ltd
KQ:065510
|
-0.009x |
|
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
|
-0.096x |
|
Perak Transit Bhd
KLSE:0186
|
-0.003x |
|
Toivo Group Oyj
HE:TOIVO
|
-0.098x |
|
G5 Entertainment publ AB
ST:G5EN
|
0.061x |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
-0.452x |
|
EURODRY LTD. DL -01
F:0LQ
|
0.074x |
Annual Cash Flow Conversion Efficiency for Yarrow Bioscience Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Yarrow Bioscience Inc from 2015 to 2025. Also see Yarrow Bioscience Inc assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.77 Million | $-33.12 Million | -1.193x | -82.91% |
| 2024-12-31 | $52.09 Million | $-33.97 Million | -0.652x | -128.39% |
| 2023-12-31 | $88.73 Million | $-25.34 Million | -0.286x | +69.48% |
| 2022-12-31 | $31.20 Million | $-29.20 Million | -0.936x | +19.25% |
| 2021-12-31 | $48.64 Million | $-56.37 Million | -1.159x | +68.30% |
| 2020-12-31 | $37.49 Million | $-137.08 Million | -3.656x | -284.75% |
| 2019-12-31 | $68.51 Million | $-65.10 Million | -0.950x | -134.94% |
| 2018-12-31 | $130.38 Million | $-52.73 Million | -0.404x | -181.67% |
| 2017-12-31 | $-57.03 Million | $-28.25 Million | 0.495x | +536.45% |
| 2016-12-31 | $-29.44 Million | $-2.29 Million | 0.078x | -70.32% |
| 2015-12-31 | $-15.95 Million | $-4.18 Million | 0.262x | -- |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more